Immune Therapeutics Clears Critical Regulatory Hurdle for Lodonal in Kenya

ORLANDO, Fla., March 17, 2017, IMUN, (GLOBE NEWSWIRE) Immune Therapeutics, Inc. (OTCQB:IMUN), a clinical-stage biopharmaceutical company developing therapies for a range of conditions using Lodonal™, its proprietary formulation of lower-dose naltrexone, announced today that the Dominican Republic Ministry of Public Health has granted Immune s request to export Lodonal to Kenya. Immune Therapeutics formulates and manufactures Lodonal in the Dominican Republic. Local laws require a Certificate of Pharmaceutical Product ( COPP ) to export Lodonal to Kenya. The granting of our export
http://bit.ly/2mXabYP